NYSEAMERICAN:CATX Perspective Therapeutics (CATX) News Today 0.30 +0.01 (+2.16%) (As of 09/22/2023 08:51 PM ET) Add Compare Share Share Today's Range0.29▼0.3150-Day Range N/A52-Week Range0.19▼0.73Volume247,800 shsAverage Volume2.45 million shsMarket Capitalization$83.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A HeadlinesProfileChartCompetitorsEarningsHeadlinesShort InterestSocial MediaProfileChartCompetitorsEarningsHeadlinesShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePerspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicinefinance.yahoo.com - September 12 at 9:53 AMPerspective Therapeutics to Present at the World Molecular Imaging Congress 2023finance.yahoo.com - August 30 at 8:33 AMPerspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicinefinance.yahoo.com - August 28 at 12:24 PMPerspective Therapeutics, Inc.: Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlightsfinanznachrichten.de - August 11 at 6:06 PMPerspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlightsfinance.yahoo.com - August 11 at 6:06 PMPerspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanomafinance.yahoo.com - August 11 at 6:06 PMPerspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimatesfinance.yahoo.com - August 11 at 6:06 PMPerspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatmentfinance.yahoo.com - August 9 at 12:52 PMCATX - Perspective Therapeutics, Inc.finance.yahoo.com - July 23 at 7:21 AMPerspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conferencefinance.yahoo.com - June 27 at 9:11 AMPerspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meetingfinance.yahoo.com - June 16 at 9:49 AMPerspective Therapeutics to Present at the 2023 Annual Society for Nuclear Medicine and Molecular Imaging Conferencefinance.yahoo.com - June 8 at 9:58 AMPerspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)finance.yahoo.com - May 24 at 9:10 AMOppenheimer Maintains Perspective Therapeutics (CATX) Outperform Recommendationmsn.com - May 19 at 11:16 PMPerspective Therapeutics reports Q1 resultsseekingalpha.com - May 16 at 3:59 PMPerspective Therapeutics, Inc.: Perspective Therapeutics Reports First Quarter Fiscal 2023 Resultsfinanznachrichten.de - May 16 at 10:31 AMPerspective Therapeutics Reports First Quarter Fiscal 2023 Resultsfinance.yahoo.com - May 15 at 11:54 PMPerspective Therapeutics Announces Changes to the Board of Directorsfinance.yahoo.com - May 15 at 6:51 PM Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Media Mentions By Week CATX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.000.52▲Average Medical News Sentiment CATX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼01▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XAIR News Today CTSO News Today ALPA News Today CTCX News Today DRIO News Today HSAQ News Today RCLF News Today ASXC News Today EDTXF News Today INO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NYSEAMERICAN:CATX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.